公开(公告)号：EP3172234B1

公开(公告)日：2020-04-08

申请号：EP15745069.3

申请日：2015-07-21

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： KENDERIAN, Saad ,  BROGDON, Jennifer ,  EBERSBACH, Hilmar ,  GILL, Saar ,  GLASS, David ,  HUBER, Thomas ,  JASCUR, Julia ,  MANNICK, Joan ,  MILONE, Michael C. ,  MURPHY, Leon ,  RICHARDSON, Celeste ,  SINGH, Reshma ,  SONG, Huijuan ,  WU, Qilong ,  ZHANG, Jiquan

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K14/725 ,  C07K14/705 ,  A61K39/395 ,  A61K31/436 ,  A61K35/17 ,  A61P35/02

公开(公告)号：EP2953969B1

公开(公告)日：2019-08-28

申请号：EP14708950.2

申请日：2014-02-07

申请人： Novartis AG

发明人： DI PADOVA, Franco, E. ,  HUBER, Thomas ,  RONDEAU, Jean-Michel, Rene

IPC分类号： C07K14/54 ,  C07K16/24 ,  A61K39/395

公开(公告)号：EP3310813A1

公开(公告)日：2018-04-25

申请号：EP16732342.7

申请日：2016-06-17

申请人： Novartis AG

发明人： ABRAMS, Tinya ,  COHEN, Steven ,  D'ALESSIO, Joseph Anthony ,  DAMIANO, Jason ,  DURR, Clemens ,  GEIERSTANGER, Bernhard Hubert ,  HU, Qi-Ying ,  HUBER, Thomas ,  IMASE, Hidetomo ,  JIN, Yunho ,  MENEZES, Daniel ,  MILLER, Kathy ,  MOHSENI, Morvarid ,  OU, Weijia ,  RENDAHL, Katherine ,  UNO, Tetsuo ,  WAN, Yongqin ,  WANG, Xing

IPC分类号： C07K16/28 ,  A61K31/00 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/28 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：EP2953969A1

公开(公告)日：2015-12-16

申请号：EP14708950.2

申请日：2014-02-07

申请人： Novartis AG

发明人： DI PADOVA, Franco, E. ,  HUBER, Thomas ,  RONDEAU, Jean-Michel, Rene

IPC分类号： C07K14/54 ,  C07K16/24 ,  A61K39/395

CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

摘要： The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.